BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Agile Therapeutics Inc. Almirall Almirall S.A. Conatus Conatus Pharmaceuticals Inc. Eddingpharm Inc. Glenmark Glenmark Pharmaceuticals Ltd. ImmVira Co. Ltd. Intensity Therapeutics Intensity Therapeutics Inc. Merck Merck...
BioCentury | Jun 24, 2017
Strategy

Takeda’s modality operandi

Takeda Pharmaceutical Co. Ltd. is moving beyond its traditional small molecule approach into new modalities with the goal of delivering therapeutics that provide a step change for patients. To get there, Takeda is using a...
BioCentury | Jun 2, 2017
Clinical News

Intensity begins Phase I/II of INT230-6 in advanced solid tumors

...and pharmacokinetics as secondary endpoints. INT230-6 is an intratumoral aqueous solution comprising cisplatin and vinblastine. Intensity Therapeutics Inc....
...advanced solid tumors Endpoint: Safety; tumor response and pharmacokinetics Status: Phase I/II started Milestone: NA Julian Zhu INT230-6 Intensity Therapeutics Inc. Dendritic...
BioCentury | Jul 11, 2016
Financial News

Intensity Therapeutics completes venture financing

Intensity Therapeutics Inc. , Westport, Conn. Business: Drug delivery, Cancer Date completed: 2016-06-28 Type: Venture financing Raised: $10 million Investors: Batterson Venture Capital; Vcapital; FastForward Innovations Ltd.; SalvaRx Group; private investors; and other undisclosed investors WIR...
BioCentury | Jun 29, 2016
Financial News

Intensity raises $10M in series A

Intensity Therapeutics Inc. (Westport, Conn.) said it raised $10 million in an oversubscribed series A financing from Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group, Declan Doogan and Jim Mellon, plus other undisclosed investors including...
BioCentury | Sep 8, 2014
Company News

Intensity Therapeutics management update

Intensity Therapeutics Inc. , Westport, Conn. Business: Cancer, Drug delivery Hired: Ian Walters as VP of clinical development and CMO WIR Staff...
BioCentury | Jun 2, 2014
Company News

Intensity Therapeutics, NIH deal

...has control over the patenting process and an option for exclusive licenses to the IP. Intensity Therapeutics Inc....
BioCentury | Feb 10, 2014
Emerging Company Profile

Intensity: More with less

...claims for products with the enhancers. COMPANIES & INSTITUTIONS MENTIONED Intensity Therapeutics Inc. , Norwalk, Conn. Sidebars Intensity Therapeutics Inc....
Items per page:
1 - 8 of 8
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Agile Therapeutics Inc. Almirall Almirall S.A. Conatus Conatus Pharmaceuticals Inc. Eddingpharm Inc. Glenmark Glenmark Pharmaceuticals Ltd. ImmVira Co. Ltd. Intensity Therapeutics Intensity Therapeutics Inc. Merck Merck...
BioCentury | Jun 24, 2017
Strategy

Takeda’s modality operandi

Takeda Pharmaceutical Co. Ltd. is moving beyond its traditional small molecule approach into new modalities with the goal of delivering therapeutics that provide a step change for patients. To get there, Takeda is using a...
BioCentury | Jun 2, 2017
Clinical News

Intensity begins Phase I/II of INT230-6 in advanced solid tumors

...and pharmacokinetics as secondary endpoints. INT230-6 is an intratumoral aqueous solution comprising cisplatin and vinblastine. Intensity Therapeutics Inc....
...advanced solid tumors Endpoint: Safety; tumor response and pharmacokinetics Status: Phase I/II started Milestone: NA Julian Zhu INT230-6 Intensity Therapeutics Inc. Dendritic...
BioCentury | Jul 11, 2016
Financial News

Intensity Therapeutics completes venture financing

Intensity Therapeutics Inc. , Westport, Conn. Business: Drug delivery, Cancer Date completed: 2016-06-28 Type: Venture financing Raised: $10 million Investors: Batterson Venture Capital; Vcapital; FastForward Innovations Ltd.; SalvaRx Group; private investors; and other undisclosed investors WIR...
BioCentury | Jun 29, 2016
Financial News

Intensity raises $10M in series A

Intensity Therapeutics Inc. (Westport, Conn.) said it raised $10 million in an oversubscribed series A financing from Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group, Declan Doogan and Jim Mellon, plus other undisclosed investors including...
BioCentury | Sep 8, 2014
Company News

Intensity Therapeutics management update

Intensity Therapeutics Inc. , Westport, Conn. Business: Cancer, Drug delivery Hired: Ian Walters as VP of clinical development and CMO WIR Staff...
BioCentury | Jun 2, 2014
Company News

Intensity Therapeutics, NIH deal

...has control over the patenting process and an option for exclusive licenses to the IP. Intensity Therapeutics Inc....
BioCentury | Feb 10, 2014
Emerging Company Profile

Intensity: More with less

...claims for products with the enhancers. COMPANIES & INSTITUTIONS MENTIONED Intensity Therapeutics Inc. , Norwalk, Conn. Sidebars Intensity Therapeutics Inc....
Items per page:
1 - 8 of 8